1. Home
  2. GAU vs CSTL Comparison

GAU vs CSTL Comparison

Compare GAU & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galiano Gold Inc.

GAU

Galiano Gold Inc.

N/A

Current Price

$2.09

Market Cap

606.0M

Sector

N/A

ML Signal

N/A

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

N/A

Current Price

$29.62

Market Cap

722.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GAU
CSTL
Founded
1999
2007
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
606.0M
722.8M
IPO Year
2006
2019

Fundamental Metrics

Financial Performance
Metric
GAU
CSTL
Price
$2.09
$29.62
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$4.08
$45.50
AVG Volume (30 Days)
3.1M
470.7K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$344,229,000.00
Revenue This Year
$82.77
$2.42
Revenue Next Year
$29.09
$12.69
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.66
52 Week Low
$1.66
$17.72
52 Week High
$3.62
$44.28

Technical Indicators

Market Signals
Indicator
GAU
CSTL
Relative Strength Index (RSI) 62.54 60.34
Support Level $1.96 $22.88
Resistance Level $2.75 $34.97
Average True Range (ATR) 0.09 1.81
MACD 0.04 0.07
Stochastic Oscillator 82.41 65.06

Price Performance

Historical Comparison
GAU
CSTL

About GAU Galiano Gold Inc.

Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Share on Social Networks: